• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LIN Chenshi, CHEN Yuhong, YIN Lifang. Progress on atherosclerosis vaccine[J]. Journal of China Pharmaceutical University, 2020, 51(6): 739-747. DOI: 10.11665/j.issn.1000-5048.20200614
Citation: LIN Chenshi, CHEN Yuhong, YIN Lifang. Progress on atherosclerosis vaccine[J]. Journal of China Pharmaceutical University, 2020, 51(6): 739-747. DOI: 10.11665/j.issn.1000-5048.20200614
shu

Progress on atherosclerosis vaccine

Funds: This study was supported by the Advantage Discipline Project of Jiangsu (III)-The Disruptive Theory and Technology Innovative Research Team Project
More Information
  • Received Date: April 19, 2020
  • Revised Date: October 04, 2020
    Graphical Abstract
    • Abstract
  • Atherosclerosis is an inflammatory disease which mediated by the immune system of the arterial wall. Specific and non-specific immune systems of arterial wall showed positive immunore action with many endogenous and exogenous antigens.Studies have shown that the immune system promotes atherosclerosis on the one hand and delays atherosclerosis on the other. Therefore,the progress of atherosclerosis can be regulated through activating immune regulation. In this review,the double effects of specific and non-specific immune systems on the process of atherosclerosis were discussed. The studies of those antigen which have been made into vaccines and successfully delayed the process of atherosclerosis in laboratory models were introduced. And the prospects and challenges for future clinical application of atherosclerosis vaccines were discussed in this review.
    • FullText(HTML)
    • References (57)
  • [1]
    . Nat Immunol 2011，12（3）：204?212.
    [2]
    Yang X，Li J，Hu D，et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population：the China-PAR project （prediction for ASCVD risk in China）［J］. Circulation，2016，134（19）：1430?1440.
    [3]
    Tall AR，Yvan-Charvet L. Cholesterol，inflammation and innate immunity［J］. Nat Rev Immunol，2015，15（2）：104?116.
    [4]
    Zernecke A. Dendritic cells in atherosclerosis：evidence in mice and humans［J］. Arterioscler Thromb Vasc Biol，2015，35（4）：763?770.
    [5]
    Hovland A，Jonasson L，Garred P，et al. The complement system and Toll-like receptors as integrated players in the pathophysiology of atherosclerosis［J］. Atherosclerosis，2015，241（2）：480?494.
    [6]
    Ramji DP，Davies TS. Cytokines in atherosclerosis：key players in all stages of disease and promising therapeutic targets［J］. Cytokine Growth Factor Rev，2015，26（6）：673?685.
    [7]
    Conti P，Shaik-Dasthagirisaeb Y. Atherosclerosis：a chronic inflammatory disease mediated by mast cells［J］. Cejoi，2015，3：380?386.
    [8]
    Amengual J，Zhou F，Barrett TJ，et al. Abstract 210：beta-carotene conversion to vitamin a delays atherosclerosis progression and accelerates atherosclerosis regression［J］. Arterioscler Thromb Vasc Biol，2018，38：A210.
    [9]
    Li Y，To K，Kanellakis P，et al. CD4+ natural killer T cells potently augment aortic root atherosclerosis by perforin-and granzyme B-dependent cytotoxicity［J］. Circ Res，2015，116（2）：245?254.
    [10]
    Kohlhauer M，Berdeaux A，Ghaleh B，et al. Inflammation in atherosclerosis［J］. Retour Au Numéro，2016，48（2）：265?266.
    [11]
    Shi G，Bot I，Kovanen PT. Mast cells in human and experimental cardiometabolic diseases［J］. Nat Rev Cardiol，2015，12（11）：643?658.
    [12]
    Zernecke A. Dendritic cells in atherosclerosis［J］. Arterioscler Thromb Vasc Biol，2015：114.303566.
    [13]
    Williams JW，Huang LH，Randolph GJ. Cytokine circuits in cardiovascular disease［J］. Immunity，2019，50（4）：941?954.
    [14]
    Silvestre-Roig C，Braster Q，Ortega-Gomez A，et al. Neutrophils as regulators of cardiovascular inflammation［J］. Nat Rev Cardiol，2020，17（6）：327?340.
    [15]
    Ammirati E，Moroni F，Magnoni M，et al. The role of T and B cells in human atherosclerosis and atherothrombosis［J］. Clin Exp Immunol，2015，179（2）：173?187.
    [16]
    Panda S，Ding JL. Natural antibodies bridge innate and adaptive immunity［J］. J Immunol，2015，194（1）：13?20.
    [17]
    Rahman M，Sing S，Golabkesh Z，et al. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus：regulation and underlying mechanisms［J］. Clin Immunol，2016，166/167：27?37.
    [18]
    Hedrick CC. Lymphocytes in atherosclerosis［J］. Arterioscler Thromb Vasc Biol，2015，35（2）：253?257.
    [19]
    Lacy M，Atzler D，Liu R，et al. Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis［J］. Pharmacol Ther，2019，193：50?62.
    [20]
    Lu J，Xiang G，Liu M，et al. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice［J］. Atherosclerosis，2015，243（2）：438?448.
    [21]
    Hubackova S，Kucerova A，Michlits G，et al. IFNγ induces oxidative stress，DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2［J］. Oncogene，2016，35（10）：1236?1249.
    [22]
    Borén J，Chapman MJ，Krauss RM，et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease：pathophysiological，genetic，and therapeutic insights：a consensus statement from the European Atherosclerosis Society Consensus Panel［J］. Eur Heart J，2020，41（24）：2313?2330.
    [23]
    Potekhina AV，Pylaeva E，Provatorov S，et al. Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis［J］. Atherosclerosis，2015，238（1）：17?21.
    [24]
    Cochain C，Koch M，Chaudhari SM，et al. CD8+T cells regulate monopoiesis and circulating Ly6C-high monocyte levels in atherosclerosis in mice［J］. Circ Res，2015，117（3）：244?253.
    [25]
    Qiu MK，Wang SC，Dai YX，et al. PD-1 and tim-3 pathways regulate CD8+T cells function in atherosclerosis［J］. PLoS One，2015，10（6）：e0128523.
    [26]
    Tay C，Kanellakis P，Hosseini H，et al. B cell and CD4 T cell interactions promote development of atherosclerosis［J］. Front Immunol，2019，10：3046.
    [27]
    Simons KH，de Vries MR，Peters HAB，et al. CD8+T cells protect during vein graft disease development［J］. Front Cardiovasc Med，2019，6：77.
    [28]
    Rosenson RS，Brewer HBJr，Ansell BJ，et al. Dysfunctional HDL and atherosclerotic cardiovascular disease［J］. Nat Rev Cardiol，2016，13（1）：48?60.
    [29]
    How KY，Song KP，Chan KG. Porphyromonas gingivalis：an overview of periodontopathic pathogen below the gum line［J］. Front Microbiol，2016，7：53.
    [30]
    Antoniak DT，Duryee MJ，Mikuls TR，et al. Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease［J］. Free Radic Biol Med，2015，89：409?418.
    [31]
    Menini S，Iacobini C，Ricci C，et al. Protection from diabetes- induced atherosclerosis and renal disease by D-carnosine- octylester：effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice［J］. Diabetologia，2015，58（4）：845?853.
    [32]
    Byun YS，Lee JH，Arsenault BJ，et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy：the TNT trial［J］. J Am Coll Cardiol，2015，65（13）：1286?1295.
    [33]
    Kobiyama K，Saigusa R，Ley K. Vaccination against atherosclerosis［J］. Curr Opin Immunol，2019，59：15?24.
    [34]
    Zhao X，Chyu K，Paul CD，et al. Abstract 18244：adoptive cell transfer demonstrates that CD8+ T cells mediate the anti-atherogenic effects of the ApoB-100 peptide P210 immunization in ApoE-/- mice［J］. Circ，2010，122（21）：A18244.
    [35]
    Chyu KY，Zhao XN，Dimayuga PC，et al. CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide［J］. PLoS One，2012，7（2）：e30780. doi：10.1371/journal.pone.0030780.
    [36]
    Santos RD，Raal FJ，Catapano AL，et al. Mipomersen，an antisense oligonucleotide to apolipoprotein B-100，reduces lipoprotein（a） in various populations with hypercholesterolemia： results of 4 phase III trials［J］. Arterioscler Thromb Vasc Biol，2015，35（3）：689?699.
    [37]
    Klingenberg R，Lebens M，Hermansson A，et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis［J］. Arterioscler Thromb Vasc Biol，2010，30（5）：946?952.
    [38]
    Thota LN，Ponnusamy T，Lu X，et al. Long-term efficacy and safety of immunomodulatory therapy for atherosclerosis［J］. Cardiovasc Drugs Ther，2019，33（4）：385?398.
    [39]
    Kimura T，Tse K，McArdle S，et al. Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells［J］. Am J Physiol Heart Circ Physiol，2017，312（4）：H781?H790.
    [40]
    de Grooth GJ，Klerkx AH，Stroes ES，et al. A review of CETP and its relation to atherosclerosis［J］. J Lipid Res，2004，45（11）：1967?1974.
    [41]
    Prospective Studies Collaboration，Lewington S，Whitlock G，et al. Blood cholesterol and vascular mortality by age，sex，and blood pressure：a meta-analysis of individual data from 61 prospective studies with 55，000 vascular deaths［J］. Lancet，2007，370（9602）：1829?1839.
    [42]
    Klerkx. Major lipids，apolipoproteins，and risk of vascular disease［J］. J Vasc Surg，2010，52（2）：518?519.
    [43]
    Davidson MH，Maki K，Umporowicz D，et al. The safety and immunogenicity of a CETP vaccine in healthy adults［J］. Atherosclerosis，2003，169（1）：113?120.
    [44]
    Cesena FH，Dimayuga PC，Yano J，et al. Immune-modulation by polyclonal IgM treatment reduces atherosclerosis in hypercholesterolemic apoE-/- mice［J］. Atherosclerosis，2012，220（1）：59?65.
    [45]
    Gleissner CA，Erbel C，Haeussler J，et al. Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease［J］. Clin Res Cardiol，2015，104（1）：13?22.
    [46]
    Jakic B，Buszko M，Cappellano G，et al. Elevated sodium leads to the increased expression of HSP60 and induces apoptosis in HUVECs［J］. PLoS One，2017，12（6）：e0179383.
    [47]
    Wick C，Onestingel E，Demetz E，et al. Oral tolerization with mycobacterial heat shock protein 65 reduces chronic experimental atherosclerosis in aged mice［J］. Gerontology，2018，64（1）：36?48.
    [48]
    Zhang Y，Mu Q，Zhou Z，et al. Protective effect of irisin on atherosclerosis via suppressing oxidized low density lipoprotein induced vascular inflammation and endothelial dysfunction［J］. PLoS One，2016，11（6）：e0158038.
    [49]
    Campbell LA，Rosenfeld ME. Infection and atherosclerosis development［J］. Med Res Arch，2015，46（5）：339?350.
    [50]
    Brack MC，Lienau J，Kuebler WM，et al. Cardiovascular sequelae of pneumonia［J］. Curr Opin Pulm Med，2019，25（3）：257?262.
    [51]
    Flannery B，Chung JR，Belongia EA，et al. Interim estimates of 2017-18 seasonal influenza vaccine effectiveness-United States，February 2018［J］. MMWR Morb Mortal Wkly Rep，2018，67（6）：180?185.
    [52]
    Liaw YW，Lin CY，Lai YS，et al. A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit［J］. PLoS One，2014，9（12）：e111529. doi：10.1371/journal.pone.0111529.
    [53]
    Qi G，Li J，Wang S，et al. A chimeric peptide of intestinal trefoil factor containing cholesteryl ester transfer protein B cell epitope significantly inhibits atherosclerosis in rabbits after oral administration［J］. Peptides，2011，32（4）：790?796.
    [54]
    Salazar-Gonzalez JA，Rosales-Mendoza S，Romero-Maldonado A，et al. Production of a plant-derived immunogenic protein targeting ApoB100 and CETP：toward a plant-based atherosclerosis vaccine［J］. Mol Biotechnol，2014，56（12）：1133?1142.
    [55]
    Mao D，Kai G，Gaofu Q，et al. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis［J］. Vaccine，2006，24（23）：4942?4950.
    [56]
    Dunér P，To F，Alm R，et al. Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease［J］. J Intern Med，2009，265（5）：593?603.
    [57]
    Dunér P，To F，Beckmann K，et al. Immunization of apoE-/- mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis［J］. Cardiovasc Res，2011，91（3）：528?536.
    • Related Articles

  • Related Articles

    [1]ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
    [2]YAO Zheng, LI Zihan, GAO Liming, HU Xing, CHEN Yan, PAN Wenqi, LI Qian. Advances of research on CAR-T cell immunotherapy for solid tumors[J]. Journal of China Pharmaceutical University, 2021, 52(4): 496-504. DOI: 10.11665/j.issn.1000-5048.20210413
    [3]BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
    [4]XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
    [5]ZHANG Rui, JIANG Tao, ZENG Tianzhu, YAO Wenbing, GAO Xiangdong, TIAN Hong. Advances of combined immunotherapy in tumor[J]. Journal of China Pharmaceutical University, 2018, 49(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20180401
    [6]YANG Ruocong, DUAN Feipeng, CHAO Jiahong, TIAN Pengpeng, YAN Zhiyong, LI Shaojing. Advances of microRNA activity in innate immunity[J]. Journal of China Pharmaceutical University, 2017, 48(4): 396-406. DOI: 10.11665/j.issn.1000-5048.20170403
    [7]JIANG Lu, CHEN Dandan, SUN Minjie, PING Qineng, ZHANG Can. Advances of wax matrix tablets[J]. Journal of China Pharmaceutical University, 2016, 47(4): 497-502. DOI: 10.11665/j.issn.1000-5048.20160418
    [8]YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
    [9]DENG Danni, TIAN Hong, YAO Wenbing. Advances in therapeutic B-cell vaccines against chronic diseases[J]. Journal of China Pharmaceutical University, 2013, 44(5): 470-475. DOI: 10.11665/j.issn.1000-5048.20130517
    [10]SUN Zhan-yi, CAI Hui, HUANG Zhi-hua, SHI Lei, CHEN Yong-xiang, LI Yan-mei. Advances of glycopeptide-associated tumor vaccines[J]. Journal of China Pharmaceutical University, 2012, 43(2): 97-106.

  • Cited by

    Periodical cited type(0)

    Other cited types(6)

Catalog

    Get Citation
    PDF
    XML
    Article views (278) PDF downloads (814) Cited by(6)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：275962

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return